Medknow Publications on behalf of the Neurological Society of India
Vol. 56, No. 3, 2008, pp. 333-338
Bioline Code: ni08084
Full paper language: English
Document type: Review Article
Document available free of charge
Neurology India, Vol. 56, No. 3, 2008, pp. 333-338
© Copyright 2008 Neurology India.
Two eminently treatable genetic metabolic myopathies|
Treatment of the genetic metabolic myopathies remains generally unsatisfactory with the exception of a select few. Multiple Acyl Co-A Dehydrogenase Deficiency (Glutaric Aciduria type II), in particular, has been shown to respond well to riboflavin supplementation. Recently, studies have also confirmed the effectiveness of recombinant enzyme replacement therapy for Acid Maltase Deficiency (Pompe′s Disease). Accurate and early diagnosis of these diseases is vital to prevent serious complications and impaired recovery following delayed treatment.
Acid maltase deficiency, enzyme replacement therapy, glutaric aciduria Type II, human recombinant α-glucosidase, multiple Co-A dehydrogenase deficiency, Pompe disease, riboflavin
Alternative site location: http://www.neurologyindia.com